Precision at the Point of Injury

Biomaterials that
heal, seal,
and protect.

Arogya Biotechnologies engineers next-generation biomaterials for critical unmet needs in surgery and wound care. Our first platform, HemoSeal, addresses life-threatening surgical bleeding where current sealants fall short.

Explore HemoSeal → Investor Inquiries

The Challenge

Surgical bleeding is a solved problem — except when it isn't

Uncontrolled hemorrhage remains a leading cause of preventable death across surgery, trauma, and combat medicine — not because solutions don't exist, but because every available product breaks down precisely when and where it matters most: in wet, dynamic, infected, or hard-to-reach tissue environments where reliable sealing, flexible adhesion, and infection control are simultaneously required.

$2.7B+

Global surgical sealant market in 2025, projected to grow significantly through 2030 [1]

~30%

Of trauma fatalities are attributable to hemorrhage — the leading cause of preventable death in trauma [2]

~50M

Inpatient surgical procedures performed annually in the US, with millions requiring active hemostasis [3]

Currently approved antibacterial sealants for infected wound fields

01
Poor wet adhesion. Leading sealants wash away in actively bleeding fields, requiring surgeons to temporarily halt blood flow before application — a significant limitation in emergent scenarios.
02
No antibacterial activity. None of the currently approved sealants address the risk of post-operative infection at the wound site, a leading driver of surgical complications and hospital costs.
03
Mechanical mismatch. Rigid or brittle sealants fail at the interface with elastic tissues like lung, bowel, and vascular structures, leading to rebleeding and sealant detachment.
04
Limited minimally invasive access. Most sealants cannot be injected through standard laparoscopic or endoscopic ports, restricting their utility in the fastest-growing segment of surgery.

Our Solution

Introducing HemoSeal

Read the Publication →

HemoSeal is a next-generation injectable hemostatic sealant designed to simultaneously address several key limitations of currently available products — in a single, multifunctional material.

Strong wet-tissue adhesion — bonds reliably to actively bleeding tissue without requiring a dry operative field
Broad-spectrum antibacterial activity — inhibits bacterial growth without relying on antibiotics, reducing the risk of post-operative infection
Mechanically matched to soft tissue — elastic and flexible, conforming to dynamic anatomical structures such as lung, bowel, and vasculature
Injectable and minimally invasive — deliverable through standard laparoscopic or endoscopic ports for use in modern surgical workflows
Biodegradable and biocompatible — designed to safely resorb over time with a favorable safety profile

Technology Highlights

What makes HemoSeal different

No blood-derived materials

Fully synthetic formulation avoids the risks of pathogen transmission and immunogenic reactions associated with fibrin or thrombin-based products.

No compression required

Achieves hemostasis through adhesion alone — no manual compression needed, even in hard-to-reach anatomy where pressure-based hemostats are impractical.

Multi-organ applicability

Tunable mechanical properties allow HemoSeal to conform to and seal diverse soft tissues — lung, liver, bowel, vasculature — without detachment under cyclic motion.

Dual hemostatic + antibacterial action

Designed to combine active hemorrhage control with intrinsic antibacterial protection — tackling two of surgery's most critical complications in a single material, with no antibiotic dependence.

Injectable through MIS ports

Syringeable through standard laparoscopic and endoscopic port sizes, enabling hemostatic sealing in minimally invasive procedures.

Rapid on-demand gelation

Photo-activated crosslinking enables near-instantaneous gelation at the point of application — precise spatial and temporal control when it matters most.

Applications

Built for the highest-stakes clinical environments

General & MIS Surgery

Laparoscopic and open abdominal procedures involving the liver, spleen, bowel, and kidney where hemorrhage control and infection prevention are both critical.

Thoracic & Pulmonary Surgery

Bronchoscopic and open thoracic procedures requiring a sealant that conforms to lung parenchyma and maintains adhesion under respiratory motion.

Trauma Surgery

Penetrating and blunt trauma with internal hemorrhage, where rapid application and wet-field performance are decisive.

Military & Battlefield Medicine

Forward-deployed environments where injectable hemostats with built-in infection control can reduce preventable casualty mortality without OR access.

Emergency Medical Services

Pre-hospital bleeding control by paramedics and first responders in the critical window before hospital arrival.

Preclinical Validation

In vitro hemostasis, wet-tissue adhesion, antibacterial efficacy, and biocompatibility validated and published in Advanced Science (2025).

Team

Science driven

Saumya Jain, PhD

Founder & CEO

saumya@arogyabiotechnologies.com

PhD in Chemical Engineering, UCLA. Inventor of the HemoSeal platform technology. 14 peer-reviewed publications including first-author papers in Science Translational Medicine and Advanced Science. Two filed patents. Deep expertise in hydrogel design, nanoparticle drug delivery, and tissue engineering.

Scientific & Clinical Advisors

Nasim Annabi, PhD

Scientific Advisor & PhD Supervisor · Associate Professor of Chemical Engineering, UCLA · Director, Annabi Biomaterials & Bioengineering Lab · Co-founder, GelMEDIX · Pioneer in photo-crosslinkable hydrogels for cardiovascular, pulmonary, and wound-healing applications, with over 100 peer-reviewed publications and multiple FDA-track technologies in development.

George Cheng, MD/PhD

Clinical Advisor · Interventional Pulmonologist & Assistant Professor of Medicine, UC San Diego · Co-founder, Restor3d · Specialist in bronchoscopic and minimally invasive thoracic procedures, with deep expertise in the clinical unmet needs surrounding airway and pulmonary hemorrhage — the primary target indication for HemoSeal's first-in-human study.

News & Awards

Momentum building

Jun 2026

NSF I-Corps National Program

Awarded NSF I-Corps Teams grant and selected for the National Program cohort — a competitive customer discovery initiative designed to accelerate deep-tech commercialization.

Jun 2026

Incorporated

Arogya Biotechnologies, Inc. formally incorporated in California.

May 2026

LA Best MedTech Demo Track — Won First Place Award

HemoSeal won First Place in the pitch competition at LA Best MedTech, selected from a competitive field of emerging medical device and biotechnology companies across the Los Angeles region.

LA Best MedTech Demo Track First Place win

Apr 2026

Taiwan Selects LA — Invited to Pitch

Selected to present HemoSeal at Taiwan Selects LA, a curated program connecting high-potential life sciences startups with international strategic partners and investors.

Mar 2026

MedTech Innovator — Invited to Pitch

Selected to pitch at MedTech Innovator, one of the most competitive medtech accelerator programs globally, with a 10% acceptance rate among applicants worldwide.

Sep 2025

Publication in Advanced Science

HemoSeal platform technology published in Advanced Science (Wiley), a high-impact peer-reviewed journal.

Biomaterials that heal, seal, and protect.